Medicine Grade Bromocriptine Mesylate Powder CAS 22260-51-1

Factory Supplier for High Quality Bromocriptine Mesylate Powder CAS 22260-51-1

• Product description

• Product name	Bromocriptine mesylate
  CAS No.	22260-51-1
  Molecular Formula	C33H44BrN5O8S
  Molecular weight	750.7
  Grade Standard	Medicine Grade
  COA	Avaliable

• Product introduction

• Bromocriptine mesylate is an ergot derivative with potent dopamine receptor agonist activity. Bromocriptine mesylate is chemically designated as 2-bromoergocryptine monomethanesulfonate (salt). Bromocriptine mesylate is a white or slightly colored, fine crystalline powder odorless or having a weak characteristic odor.

  Bromocriptine mesylate is a dopamine receptor agonist, which activates postsynaptic dopamine receptors. The dopaminergic neurons in the tuberoinfundibular process modulate the secretion of prolactin from the anterior pituitary by secreting a prolactin inhibitory factor (thought to be dopamine); in the corpus striatum the dopaminergic neurons are involved in the control of motor function. Clinically, bromocriptine mesylate significantly reduces plasma levels of prolactin in patients with physiologically elevated prolactin as well as in patients with hyperprolactinemia. The inhibition of physiological lactation as well as galactorrhea in pathological hyperprolactine-mic states is obtained at dose levels that do not affect secretion of other tropic hormones from the anterior pituitary. Experiments have demonstrated that bromocriptine induces long lasting stereotyped behavior in rodents and turning behavior in rats having unilateral lesions in the substantia nigra. These actions, characteristic of those produced by dopamine, are inhibited by dopamine antagonists and suggest a direct action of bromocriptine on striataldopamine receptors. Bromocriptine mesylate is a nonhormonal, nonestrogenic agent that inhibits the secretion of prolactin in humans, with little or no effect on other pituitary hormones, except in patients with acromegaly, where it lowers elevated blood levels of g rowth hormone in the majority of patients.

• Product application

It can inhibit the secretion of PRL and LH, activate the dopamine receptors of the new striatum in the brain, and control the tremor paralysis syndrome;

It relaxes vascular smooth muscle through central or peripheral action, reduces the excitability of sympathetic nerves, and then lowers blood pressure without increasing pulse rate.